Prognostic values of C-reactive protein levels on clinical outcome after mplantation of sirolimus-eluting stents in patients on hemodialysise

37Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Background - Percutaneous coronary intervention (PCI) using drug-eluting stents significantly reduces the risk of restenosis in the general population. However, in patients on hemodialysis, adverse cardiac events are frequently seen even if treated with drug-eluting stents. Recent studies suggest that C-reactive protein (CRP) reflects vascular wall inflammation and can predict adverse cardiac events. We evaluated possible prognostic values of CRP on outcomes in patients on hemodialysis undergoing PCI with drug eluting stents. Methods and Results - A total of 167 patients undergoing PCI with sirolimus-eluting stents for stable angina (322 lesions) were enrolled. They were divided into tertiles according to serum CRP levels. We analyzed the incidence of major adverse cardiovascular events including cardiovascular death, nonfatal myocardial infarction, and target lesion revascularization after PCI as well as quantitative coronary angiographic data. The mean follow-up was 31 months (SD, 14). Major adverse cardiac events occurred in 11 patients (19.6%) of the lowest tertile, in 22 patients (39.3%) of the middle tertile, and in 28 patients (50.9%) of the highest tertile during follow-up period (P=0.0009). There was a progressive increase in neointimal growth after sirolimus-eluting stent implantation during follow-up because preprocedural CRP levels were higher, despite similar angiographic data just after PCI. Angiographic restenosis at 6 to 8 months after PCI was seen in 10.6% in the lowest tertile, 17.9% in the middle tertile, and 32.0% in the highest tertile (P=0.0007). Conclusions - Increased preprocedural serum CRP levels would predict higher major adverse cardiac events and restenosis rates after sirolimus-eluting stents implantation in patients on hemodialysis. Copyright © 2009 American Heart Association, Inc.

References Powered by Scopus

Inflammation in atherosclerosis

7367Citations
N/AReaders
Get full text

Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery

4190Citations
N/AReaders
Get full text

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization

3986Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Primary prevention of coronary heart disease: Integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey

212Citations
N/AReaders
Get full text

Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease -a perspective

94Citations
N/AReaders
Get full text

Prognostic value of reduced left ventricular ejection fraction at start of hemodialysis therapy on cardiovascular and all-cause mortality in end-stage renal disease patients

87Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ishii, H., Toriyama, T., Aoyama, T., Takahashi, H., Amano, T., Hayashi, M., … Murohara, T. (2009). Prognostic values of C-reactive protein levels on clinical outcome after mplantation of sirolimus-eluting stents in patients on hemodialysise. Circulation: Cardiovascular Interventions, 2(6), 513–518. https://doi.org/10.1161/CIRCINTERVENTIONS.109.889915

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 7

47%

Researcher 5

33%

Professor / Associate Prof. 2

13%

Lecturer / Post doc 1

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 11

65%

Agricultural and Biological Sciences 4

24%

Psychology 2

12%

Save time finding and organizing research with Mendeley

Sign up for free